Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session 2

269MO - The effects of exercise on sexual health and breast cancer-specific symptom burden in women with metastatic breast cancer: Results of the multinational randomized PREFERABLE-EFFECT trial

Date

17 May 2024

Session

Mini Oral session 2

Topics

Supportive Care and Symptom Management;  Survivorship

Tumour Site

Breast Cancer

Presenters

Martina Schmidt

Citation

Annals of Oncology (2024) 9 (suppl_4): 1-12. 10.1016/esmoop/esmoop103324

Authors

M.E. Schmidt1, A. Hiensch2, J. Depenbusch3, D. Clauss4, E. Monninkhof2, M. Pelaez5, N. Gunasekara4, M. Lachowicz6, M. Trevaskis7, H. Rundqvist8, J. Müller9, J. Wiskemann9, E. van der Wall2, N. Aaronson10, A. Urruticoechea5, E. Zopf7, M. Stuiver10, Y. Wengstrom11, A.M. May2, K. Steindorf3

Author affiliations

  • 1 DKFZ - German Cancer Research Center, Heidelberg/DE
  • 2 UMC - University Medical Center Utrecht, Utrecht/NL
  • 3 German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, a partnership between DKFZ and University Medical Center Heidelberg, Heidelberg/DE
  • 4 German Sport University Cologne, Köln/DE
  • 5 OSI Donostialdea - Onkologikoa Foundation, San Sebastian/ES
  • 6 Medical University of Gdansk, Gdansk/PL
  • 7 Australian Catholic University, Brisbane/AU
  • 8 Karolinska Institutet, Stockholm/SE
  • 9 Heidelberg University Hospital, and NCT Heidelberg, Heidelberg/DE
  • 10 Netherlands Cancer Institute, Amsterdam/NL
  • 11 Karolinska Institutet, Huddinge/SE

Resources

This content is available to ESMO members and event participants.

Abstract 269MO

Background

Women with metastatic breast cancer (mBC) experience breast cancer- and treatment-related side effects that impair activities of daily living. Evidence for exercise effects on rarely addressed problems such as sexual health or body image is lacking to date, especially for patients with advanced disease. Thus, we investigated the effects of a structured exercise intervention in women with mBC on sexual health and breast cancer-specific symptoms.

Methods

The multinational EFFECT study, including 355 women (and 2 men) with mBC from 5 European countries and Australia, randomly assigned participants to either usual care (UC) or a 9-month supervised exercise program (EX) combining aerobic, resistance, and balance exercises. All participants received general exercise advice and an activity tracker. Breast cancer-specific symptoms (EORTC QLQ-BR45) were assessed at baseline, 3, 6 (primary timepoint), and 9 months. Intervention effects were analyzed on an intent-to-treat basis with mixed models for repeated measures, adjusted for baseline values of the outcome variable and stratification factors (line of treatment and study center).

Results

Female participants had a mean ± SD age of 55.4 ± 11.1 years, mostly received 1st/second-line treatment at study enrollment (74.8%) and had bone metastases (67.5%). At baseline, sexual functioning (17.1±21.2) was low, associated with older age and depressive symptoms. Almost half of sexually active women reported little sexual enjoyment, 26% of all participants reported moderate-to-severe endocrine sexual symptoms and 24% a poor body image. Exercise improved sexual functioning (effect size (ES)=0.28, p=.0031) and endocrine sexual symptoms (ES=0.25, p=.0026) at 6-month. The exercise effect on sexual functioning was sustained at 9-month (ES=0.23, p=.020).

Conclusions

Women with mBC are likely to experience sexual problems and may have an impaired body image. Exercise can help improve sexual health in these patients. Further research should determine the optimal role of exercise in addressing symptom burden, possibly in conjunction with additional support.

Clinical trial identification

NCT04120298.

Legal entity responsible for the study

PREFERABLE consortium.

Funding

European Union’s Horizon 2020 research and innovation program (No 825677) and the National Health and Medical Research Council of Australia (2018/GNT1170698).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.